Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (Q28280465)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)	scientific article

Statements

scholarly article

0 references

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (English)

0 references

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

object named as

Kim A Papp

1

1 reference

ORCID Public Data File 2021

Mark G. Lebwohl

3

object named as

Mark Lebwohl

0 references

author name string

Richard G Langley

2

0 references

Gerald G Krueger

4

0 references

Philippe Szapary

5

0 references

Newman Yeilding

6

0 references

Cynthia Guzzo

7

0 references

Ming-Chun Hsu

8

0 references

Yuhua Wang

9

0 references

Shu Li

10

0 references

Lisa T Dooley

11

0 references

Kristian Reich

12

0 references

language of work or name

0 references

publication date

17 May 2008

0 references

0 references

371

0 references

9625

0 references

1675-84

0 references

Pathogenesis and therapy of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of cardiovascular risk factors in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of Myocardial Infarction in Patients With Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to treatment in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Objective assessment of compliance with psoriasis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960726-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28280465&oldid=2273831883"